Derrell D. Porter
Independent DirectorDr. Derrell D. Porter, M.B.A., M.D., serves as Chief Executive Officer, Secretary, and Director at cTRL Therapeutics USA, Inc. since November 2023. He serves as Independent Director at Acumen Pharmaceuticals, Inc. since January 4, 2023. He serves as Independent Director at Passage Bio, Inc. since May 27, 2021. He also serves as Director at Biosortia Pharmaceuticals, Inc. He served as Board Member at Portal Innovations, LLC until August 2026. He served as Senior VP & Global Commercial Head at Atara Biotherapeutics, Inc. from May 10, 2017 to September 2019. He served as Vice President and Head of Commercial Planning at Gilead Sciences from April 2013 to May 2017, where he was responsible for the global commercialization and marketing of the company’s pipeline as well as long range planning for all therapeutic areas including marketed products. Prior to April 2013, he was with AbbVie, where he served as Vice President, Oncology Global Pipeline Marketing. At AbbVie, he was also part of the Western Europe & Canada regional marketing team and served as VP/GM for the US Renal Care Franchise. Before AbbVie, he was with Amgen in various oncology commercial roles and in Corporate Strategy and Business Development (M&A and in-licensing). He is Founder of Cellevolve Bio, Inc. and also served as Chief Executive Officer. He began his career at McKinsey & Company as part of the West Coast Health Care Practice. He has experience in strategy, operations, global commercialization, corporate development, clinical development, running businesses in the US and Europe, global marketing, and management consulting. Dr. Porter holds an M.D. from the Perelman School of Medicine at the University of Pennsylvania, where he was a Twenty First Century Scholar, an M.B.A. in Health Care Management from the University of Pennsylvania - The Wharton School, and a B.S. in Neuroscience & Psychobiology from the University of California, Los Angeles.
Positions
- Company NamePassage Bio, Inc.Stock CodePASGPositionIndependent Director
